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
{1}2025 年 3 月 24 日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…
Danielle Pillsbury2025 年 3 月 20 日
Model-Informed Drug Development in the Age of AI
Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…
Danielle Pillsbury2025 年 3 月 10 日
Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach
This study explores a model-based meta-analysis (MBMA) and a clinical utility index (CUI) approach to…
Danielle Pillsbury2025 年 3 月 4 日
How the US FDA MIDD paired pilot program helps sponsors
2025 年 2 月 28 日 For the past couple of decades, leading American institutions, pharmaceutical and biotechnology…
Danielle Pillsbury2025 年 2 月 28 日
